Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a Phase III trial in Nigeria.

Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O, Taylor D, McNeil L, Mehta N, Umo-Otong J, Otusanya S, Crucitti T, Abdellati S.

PLoS One. 2008;3(11):e3784. doi: 10.1371/journal.pone.0003784.

2.

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.

Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D; CS Study Group..

N Engl J Med. 2008 Jul 31;359(5):463-72. doi: 10.1056/NEJMoa0707957. Erratum in: N Engl J Med. 2008 Aug 21;359(8):877.

3.

Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.

El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, Mauck C, Absalon J, Morrow K, Mâsse B, Soto-Torres L, Kwiecien A.

AIDS. 2006 May 12;20(8):1109-16.

PMID:
16691061
4.

A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases.

Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Weir SS, Wong EL.

N Engl J Med. 1998 Aug 20;339(8):504-10.

5.

Topical microbicides for prevention of sexually transmitted infections.

Obiero J, Mwethera PG, Wiysonge CS.

Cochrane Database Syst Rev. 2012 Jun 13;(6):CD007961. doi: 10.1002/14651858.CD007961.pub2. Review.

PMID:
22696373
6.

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P.

Lancet. 2008 Dec 6;372(9654):1977-87. doi: 10.1016/S0140-6736(08)61842-5.

PMID:
19059048
7.

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J.

Lancet. 2010 Oct 16;376(9749):1329-37. doi: 10.1016/S0140-6736(10)61086-0.

8.

SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.

Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W.

PLoS One. 2008 Jan 23;3(1):e1474. doi: 10.1371/journal.pone.0001474.

9.

Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial.

Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Tweedy KG.

JAMA. 2002 Mar 6;287(9):1117-22.

PMID:
11879108
10.

Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.

Malonza IM, Mirembe F, Nakabiito C, Odusoga LO, Osinupebi OA, Hazari K, Chitlange S, Ali MM, Callahan M, Van Damme L.

AIDS. 2005 Dec 2;19(18):2157-63.

PMID:
16284466
11.

Behavioral interventions for improving condom use for dual protection.

Lopez LM, Otterness C, Chen M, Steiner M, Gallo MF.

Cochrane Database Syst Rev. 2013 Oct 26;(10):CD010662. doi: 10.1002/14651858.CD010662.pub2. Review.

PMID:
24163112
12.

Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).

McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C; MTN-004 Protocol Team..

AIDS. 2011 May 15;25(8):1057-64. doi: 10.1097/QAD.0b013e328346bd3e.

13.

Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.

Abaasa A, Crook A, Gafos M, Anywaine Z, Levin J, Wandiembe S, Nanoo A, Nunn A, McCormack S, Hayes R, Kamali A.

Trials. 2013 Feb 1;14:33. doi: 10.1186/1745-6215-14-33.

14.

SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana.

Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, Rountree W, Troxler A, Dominik R, Roddy R, Dorflinger L.

PLoS One. 2007 Dec 19;2(12):e1312.

15.

The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection.

Marais D, Gawarecki D, Allan B, Ahmed K, Altini L, Cassim N, Gopolang F, Hoffman M, Ramjee G, Williamson AL.

Antivir Ther. 2011;16(8):1219-26. doi: 10.3851/IMP1890.

PMID:
22155903
16.

Interim data monitoring to enroll higher-risk participants in HIV prevention trials.

Halpern V, Obunge O, Ogunsola F, Otusanya S, Umo-Otong J, Wang CH, Mehta N.

BMC Med Res Methodol. 2009 Jun 23;9:44. doi: 10.1186/1471-2288-9-44.

17.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group..

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Erratum in: Science. 2011 Jul 29;333(6042):524.

18.

The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial.

Ramjee G, van der Straten A, Chipato T, de Bruyn G, Blanchard K, Shiboski S, Cheng H, Montgomery E, Padian N; MIRA team..

PLoS One. 2008;3(10):e3488. doi: 10.1371/journal.pone.0003488.

19.

A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.

Mbopi-Keou FX, Trottier S, Omar RF, Nkele NN, Fokoua S, Mbu ER, Domingo MC, Giguère JF, Piret J, Mwatha A, Mâsse B, Bergeron MG.

Contraception. 2010 Jan;81(1):79-85. doi: 10.1016/j.contraception.2009.07.002.

PMID:
20004278
20.

HPTN 035 phase II/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women.

Guffey MB, Richardson B, Husnik M, Makanani B, Chilongozi D, Yu E, Ramjee G, Mgodi N, Gomez K, Hillier SL, Karim SA; HIV Prevention Trials Network (HPTN) 035 Study Team..

Sex Transm Infect. 2014 Aug;90(5):363-9. doi: 10.1136/sextrans-2014-051537.

Items per page

Supplemental Content

Support Center